Le Lézard
Classified in: Business
Subject: PER

Robert Caporale Joins Gen II Fund Services as Head of Strategic Business Development


NEW YORK, Oct. 19, 2020 /PRNewswire/ -- Gen II Fund Services, LLC ("Gen II"), a leading independent private equity fund administrator, announced today that Robert Caporale has joined the firm as Head of Strategic Business Development. Mr. Caporale, a seasoned fund administration and alternative investments executive, will focus on developing strategic client partnerships and acquisition opportunities.

Most recently, Mr. Caporale was CEO of Exchangelodge, a software company that provides mission critical data solutions to the alternative investment industry.  Prior to Exchangelodge, he spent 12 years at JPMorgan where he held various senior positions within the Securities and Fund Services business, including Head of U.S. Sales, Head of Alternative Investment Services, CEO and Founder of Private Equity Fund Services, and Head of Strategic Business Development.  He also spent six years at Deutsche Bank and eight years at IBM prior to his tenure at JPMorgan.  Mr. Caporale was inducted into the Global Custodian Hall of Fame in 2013.

"We are very excited about Robert joining Gen II," said Norman Leben, Co-Founder and Managing Principal, Gen II. "Robert's knowledge of private equity fund administration and extensive experience within the alternative investment industry will be crucial in identifying partnership and acquisition opportunities to further advance Gen II's business development objectives."

"The addition of an experienced and well-respected executive like Robert to the Gen II team signifies our deep commitment to professional excellence and to the continued growth of our firm," said Steven Millner, Co-Founder and Managing Principal, Gen II.

"I'm extremely pleased to be joining the Gen II team," said Mr. Caporale. "I have known Norman and Steven for 15 years and always held them and Gen II in the highest regard.  I am excited to join them at a time of significant growth for the firm.  The Gen II team is a world class group of professionals that have an outstanding reputation in the private equity fund administration industry."

About Gen II
Gen II is one of the largest independent private equity fund administrators, administering over $350 billion of private capital on behalf of its clients with offices in New York, San Francisco, Boston, Stamford, Dallas, and Luxembourg.  Gen II offers private fund sponsors a best-in-class combination of people, process, and technology, enabling fund sponsors to effectively manage their operational infrastructure, financial reporting, and investor communications.  The Gen II team is the most experienced and longest tenured team in the private equity fund administration industry, with broad expertise across buyout, funds of funds, real estate, energy, infrastructure, credit, co-investment, hybrid funds, feeder funds, venture capital, retail, and managed accounts. For more information, please visit www.gen2fund.com.

Contact:
Philip Nunes
BackBay Communications
(617) 391-0792
[email protected]

SOURCE Gen II Fund Services, LLC


These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Galantas Gold Corporation (the ?Company') is pleased to announce its audited annual financial results for the year ended December 31, 2023. A copy of the Financial Statements and Management Discussion and Analysis will be sent to shareholders in due...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
ICEYE, a global leader in satellite-powered disaster management solutions, has announced a new data collaboration with Juniper Re, LLC ("Juniper Re"), the dynamic reinsurance broking arm and indirect subsidiary of BRP Group, Inc. . Juniper Re will...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 01:54
Continuous efforts to improve profits, competitiveness, and cash flowQ1/2024 (year-on-year) Sales decreased by 20% to EUR 2,164 (2,721) million.Adjusted EBIT decreased to EUR 156 (234) million.Adjusted EBIT margin was 7.2% (8.6%).Operating result...



News published on and distributed by: